Biotage AB and McMaster University sign joint agreement to develop new chemistry platform
Biotage AB and McMaster University signed a joint agreement to develop a new chemistry platform to speed the production of molecular imaging and therapy agents. As part of the agreement, Biotage will provide funding and instruments. The McMaster Institute of Applied radiation Sciences (McIARS) will apply funding and equipment to speed the development of novel molecular imaging agents for PET and SPECT and radiotherapy agents for treatment applications. According to the company, Biotage is the only company that offers solutions for synthesis, purification and evaporation, providing instruments and consumables for these key development steps.
"This partnership brings together cutting edge synthesis and purification tools with radiopharmaceutical research which spans basic science to the development and testing of novel imaging and therapy agents. The new platform technologies will facilitate the process of producing tracers and therapeutics and it will be particularly useful for developing radiolabeled analogues of new drug candidates. The latter aim is particularly important as imaging is playing an increasingly important role in early clinical trials," Dr. John F. Valliant, Associate Professor of Chemistry and Medical Physics, and Acting Director of McIARS stated.
Other news from the department science
![[Fe]-hydrogenase catalysis visualized using para-hydrogen-enhanced nuclear magnetic resonance spectroscopy](https://img.chemie.de/Portal/News/675fd46b9b54f_sBuG8s4sS.png?tr=w-712,h-534,cm-extract,x-0,y-16:n-xl)
